

**510(k) Summary of Safety and Effectiveness****General Provisions**

The name of the device is:

Proprietary Name	Common or Usual Name
Precise™ Nitinol Stent Transhepatic Biliary System	Biliary Stent

**Name of Predicate Devices**

The device is substantially equivalent to:

- Cordis S.M.A.R.T.™ .018" Nitinol Stent Transhepatic Biliary System (510(k) # K993646 – November 28, 1999).

**Classification**

Class II.

**Performance Standards**

Performance standards have not been established by the FDA under section 514 of the Food, Drug and Cosmetic Act.

**Indications for Use**

The **Precise™ Nitinol Stent Transhepatic Biliary System** is intended for use in the palliation of malignant neoplasms in the biliary tree.

**Device Description**

The device description of the proposed **Precise™ Nitinol Stent Transhepatic Biliary System** is as follows.

- 5.0 / 5.5 French stent delivery system profile;
- Stent material – Nickel Titanium alloy;
- Expanded stent diameters 5, 6, 7, and 8 mm;
- Stent lengths: 20, 30, and 40 mm;
- Stent delivery system usable length 135 cm; and
- Guidewire lumen 0.018".

**Biocompatibility**

All materials used in the **Precise™ Nitinol Stent Transhepatic Biliary System** are biocompatible.

**Summary of Substantial Equivalence**

The **Precise™ Nitinol Stent Transhepatic Biliary System** is substantially equivalent to the predicate device. The equivalence was confirmed through pre-clinical testing.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**MAR 1 6 2001**

Mr. Sam Mirza  
Manager, Regulatory Affairs  
Cordis Corporation  
P.O. Box 025700  
Miami, Florida 33102-5700

Re: K010445  
Precise™ Nitinol Stent Transhepatic Biliary System  
Regulatory Class: II  
21 CFR §876.5010  
Product Code: 78 FGE  
Dated: February 12, 2001  
Received: February 14, 2001

Dear Mr. Mizra:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. *Please note:* this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification if the limitation statement above is added to your labeling, as described.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR §807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

  
for Bernard E. Statland, M.D., Ph.D.  
Director  
Office of Device Evaluation  
Center for Devices and  
Radiological Health


Enclosure

510(k) Number (if known): K010445

Device Name: Precise™ Nitinol Stent Transhepatic Biliary System

FDA's Statement of the Indications For Use for device:

The Precise™ Nitinol Stent Transhepatic Biliary System is indicated for use in the palliation of malignant neoplasms in the biliary tree. The device is not intended for use in the cardiovascular system.

  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number K010445

Prescription Use ☒ OR Over-The-Counter Use ☐  
(Per 21 CFR 801.109)